Drug preparation for treating chronic diabetic ulcers and preparation method thereof

A pharmaceutical preparation, a technology for chronic ulcers, applied in the field of medicine, can solve problems such as inability to achieve effects, and achieve the effects of inhibiting the production of inflammation, improving the curative effect, and promoting migration

Active Publication Date: 2018-08-03
ZHEJIANG UNIV +1
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of drugs with a single pharmacological effect often cannot achieve the desired effect

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Drug preparation for treating chronic diabetic ulcers and preparation method thereof
  • Drug preparation for treating chronic diabetic ulcers and preparation method thereof
  • Drug preparation for treating chronic diabetic ulcers and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Example 1: Cytotoxicity Test (HSF)

[0057] 1. Culture skin fibroblasts in DMEM high-sugar medium (containing 10% inactivated fetal bovine serum, 1% double antibody (penicillin+streptomycin)), after the cells are confluent, digest the cells with trypsin, After gently tapping, add culture medium to stop digestion, carefully collect cells in a centrifuge tube, centrifuge, remove supernatant, resuspend cells and count. Adjust the cell suspension concentration to 2×10 4 cell / ml, and then add 200ul of cell suspension to each well of the 96-well plate (the edge wells are filled with sterile PBs). 5%CO 2 , incubated at 37°C, and adhered to the wall overnight until the cell monolayer covered the bottom of the well. Remove the supernatant, add HSYA (0.1, 0.2, 0.4mM), DFO (0.01875, 0.0375, 0.075, 0.15, 0.3mM) and their mixed solution with gradient concentration, 200ul per well, and set 5 duplicate wells for each concentration. At the same time, a blank control group (200ul cu...

Embodiment 2

[0063] Embodiment 2: Anti-inflammatory experiment

[0064] 1. Culture the mononuclear macrophage cell line Raw264.7 in DMEM high-glucose medium (containing 10% inactivated fetal bovine serum, 1% double antibody (penicillin+streptomycin)), after the cells are confluent, use Digest the cells with trypsin, beat gently and add culture medium to stop the digestion, carefully collect the cells in a centrifuge tube, centrifuge, remove the supernatant, resuspend the cells to adjust the cell density to 5×10 5 cell / ml, Raw264.7 was inoculated in a 96-well plate by adding 0.2ml of cell suspension to each well (the edge wells were filled with sterile PBS). After culturing, add HSYA (0.0125, 0.025, 0.05, 0.1, 0.2mM), DFO (0.0375, 0.075, 0.15) and their mixed solution for pre-incubation for 4 hours, then add 10ul of LPS with a concentration of 1ug / ml in 96 wells plate, 5% CO 2 , after culturing at 37°C for 24h, the supernatant was collected for the detection of NO content, and all experim...

Embodiment 3

[0069] Example 3: Angiogenesis experiment

[0070] 1. Thaw Matrigel in a refrigerator at 4°C. After it becomes fluid, take 50ul of Matrigel and add it to the well of a 96-well plate, and place it in a 37°C incubator for 30min. Vascular endothelial cells were digested with trypsin, tapped gently, and then culture medium was added to stop the digestion. The cells were carefully collected in a centrifuge tube, centrifuged, the supernatant was removed, and the cells were resuspended and counted. Adjust the cell suspension concentration to 1.5×10 5 cell / ml, add 100ul cell suspension to each well, then add HSYA solution (0.2, 0.4mM), DFO (0.0375) and the mixed solution of the two, 5% CO 2 , and incubated at 37°C. After 6 hours, the 96-well plate was taken out, and 2.5uM calcein was added to incubate for 30 minutes, and then the formation of blood vessels was observed under an inverted fluorescence microscope. Three replicate wells were used for each concentration.

[0071] 2. Exp...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Quality scoreaaaaaaaaaa
Login to view more

Abstract

The invention discloses a drug preparation for treating chronic diabetic ulcers, which consists of hydroxysafflor yellow A, deferoxamine mesylate and pharmaceutical excipient. In the drug preparation,the percentage by weight of the hydroxysafflor yellow A is 0.02 to 0.2 percent, and the percentage by weight of deferoxamine mesylate is 0.02 to 0.2 percent. The invention further discloses a preparation method of the drug preparation. On the basis of keeping the original pharmacological activity of the traditional Chinese medicine extract hydroxysafflor yellow A, the chemical drug, i.e. low-molecular weight deferoxamine mesylate, is jointly used by the drug preparation to enhance the neovascularization effect of the hydroxysafflor yellow A, realizing the strategy of anti-inflammation and vascular remodeling multi-target therapy and increasing the therapeutic effect of drug combination.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a pharmaceutical preparation for treating diabetic chronic ulcers and a preparation method thereof. Background technique [0002] Diabetic refractory ulcer is the main cause of amputation and disability in diabetic patients. With the increase in the number of diabetic patients worldwide, the prolongation of the life expectancy of diabetics and the trend of aging, the number of patients requiring amputation due to diabetic ulcers is also increasing. It is estimated that by 2025, there will be more than 250 million diabetic patients worldwide, and about 15% of diabetic patients will develop ulcers or gangrene. [0003] Its pathogenesis is very complex and its prognosis is poor. Studies have shown that insufficiency of blood supply and sensory loss at the extremities of the lower extremities caused by nerve and peripheral vascular lesions are the risk factors leading to the form...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/351A61K31/16A61K9/06A61K47/42A61K47/36A61P3/10A61P17/02A61P29/00
CPCA61K9/0014A61K9/06A61K31/16A61K31/351A61K47/36A61K47/42A61P3/10A61P17/02A61P29/00A61K2300/00
Inventor 高建青高思倩李平
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap